Atlanta-based Nyra designed its novel transcatheter cardiac leaflet enhancer (CARLEN) to repair FMR by augmenting the native mitral valve. CARLEN, a single-leaflet implant, aims to restore coaptation while preserving the valve’s natural motion and orifice area. It has the ability to implant on either the anterior or posterior leaflets, bringing broad clinical applicability and minimal anatomical or clinical exclusions.
CARLEN’s implantation procedure utilizes familiar echocardiographic guidance and intraprocedural imaging, the company says. It supports precise positioning and real-time assessment of valve function.
The company says its versatile design could address the anatomical and functional challenges that limited earlier therapies’ successes. Other companies are also developing innovative leaflet modification devices that center around coaptation, such as CroíValve and Pi-Cardia.
Nyra says its initial enrollment in the early feasibility study marks a significant milestone in its clinical development strategy. It follows encouraging first-in-human clinical data after the company initiated a study last fall.
The company hopes to evaluate safety, feasibility and procedural performance in patients with symptomatic functional mitral regurgitation (MR). Its study includes sites in the U.S. and Brazil, with follow-up out to five years.
Commentary from Nyra Medical officials
Lori Chmura, Chief Executive Officer of Nyra Medical, said:
“This enrollment represents more than the beginning of another clinical study. It reflects the steady execution of our long-term strategy to redefine transcatheter mitral valve repair. We have assembled an exceptional team, partnered with leading structural heart physicians, and developed a differentiated technology designed to address a substantial unmet clinical need. We believe ENHANCE EFS positions Nyra for an exciting next phase of growth as we continue building the clinical evidence supporting the CARLEN platform.”
Jennifer Mischke, SVP of clinical, regulatory & quality at Nyra Medical, said:
“The initiation of our ENHANCE early feasibility study reflects years of engineering innovation, disciplined clinical preparation, and close collaboration with world-renowned physicians. This milestone validates both the strength of our clinical development program and our commitment to bringing physicians an innovative treatment option designed to expand access to transcatheter mitral valve repair. We are excited to begin generating the clinical evidence that will support future regulatory and commercial milestones.”
